Personal information

No personal information available

Activities

Collapse all

Works (10)

The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance

Nature Genetics
2024-01 | Journal article
DOI: 10.1038/s41588-023-01592-8
Contributors: Deborah R. Caswell; Philippe Gui; Manasi K. Mayekar; Emily K. Law; Oriol Pich; Chris Bailey; Jesse Boumelha; D. Lucas Kerr; Collin M. Blakely; Tadashi Manabe et al.
Source: check_circle
Crossref

Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer

Journal of Clinical Investigation
2022-02-15 | Journal article
DOI: 10.1172/JCI156891
Contributors: Tadashi Manabe; Trever G. Bivona
Source: check_circle
Crossref

Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model.

Biochemical and biophysical research communications
2020-12-08 | Journal article
DOI: 10.1016/j.bbrc.2020.11.110
PMID: 33302159
Source: Self-asserted source
Tadashi Manabe

SHOC2 Is a Critical Modulator of Sensitivity to EGFR-TKIs in Non-Small Cell Lung Cancer Cells.

Molecular cancer research : MCR
2020-10-26 | Journal article
DOI: 10.1158/1541-7786.mcr-20-0664
PMID: 33106373
Source: Self-asserted source
Tadashi Manabe

Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study.

Journal for immunotherapy of cancer
2020-09-01 | Journal article
DOI: 10.1136/jitc-2020-001185
PMID: 32948652
PMC: PMC7511646
Source: Self-asserted source
Tadashi Manabe

IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer.

Molecular cancer research : MCR
2020-01-15 | Journal article
DOI: 10.1158/1541-7786.mcr-19-0956
PMID: 31941753
Source: Self-asserted source
Tadashi Manabe

Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab.

Molecular cancer therapeutics
2019-06-28 | Journal article
DOI: 10.1158/1535-7163.mct-18-1036
PMID: 31253648
Source: Self-asserted source
Tadashi Manabe

Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare <i>EGFR</i> mutations.

Proceedings of the National Academy of Sciences of the United States of America
2019-05-01 | Journal article
DOI: 10.1073/pnas.1819430116
PMID: 31043566
PMC: PMC6525482
Source: Self-asserted source
Tadashi Manabe

Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.

Lung cancer (Amsterdam, Netherlands)
2018-11-29 | Journal article
DOI: 10.1016/j.lungcan.2018.11.039
PMID: 30642543
Source: Self-asserted source
Tadashi Manabe

Comparison of detection methods of <i>EGFR</i> T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer.

OncoTargets and therapy
2018-06-06 | Journal article
DOI: 10.2147/ott.s161745
PMID: 29922072
PMC: PMC5995408
Source: Self-asserted source
Tadashi Manabe

Peer review (4 reviews for 1 publication/grant)

Review activity for Respiratory investigation. (4)
How many people are using ORCID?